Abstract
Increased production and viscosity of bronchial mucus could lead to the airway occlusion in patients with chronic obstructive pulmonary disease (COPD). Moreover, excessive production of the bronchial mucus could worsen clinical course of the disease and increase risk of respiratory infections. Erdosteine is a thiol derivate which modulates production and content of bronchial mucus, decreases mucus viscosity and improves mucociliary clearance. Erdosteine also has antiadhesive, antioxidant and anti-inflammatory properties. According to results of clinical trials, long-term treatment with erdosteine in a daily dose of 600 mg could improve clinical symptoms and quality of life and reduce number of exacerbations in patients with COPD. During exacerbation the dose of erdosteine could be increased up to 900 mg daily; this could improve symptoms of exacerbation, reduce local and systemic inflammatory response and shorten the duration of exacerbation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call